Free shipping $200+ · Order by 2pm CT, ships today from Tulsa, OK · Research Use Only — Not for human consumption · Documentation you can verify beats claims you have to trust · Questions? (405) 814-0022

Retatrutide (development code LY3437943) is an investigational peptide from Eli Lilly that switches on three hormone receptors at once: GIP, GLP-1 and glucagon. That makes it the first so-called triple agonist to reach late-stage clinical trials. It is being studied for obesity, type 2 diabetes and related metabolic conditions, and it is not FDA-approved.

This guide explains what retatrutide is, how it works at each of its three receptors, what its structure looks like, what the published trials have reported, and where it stands on the road to approval.

Retatrutide at a glance

DeveloperEli Lilly and Company
Code nameLY3437943
TypeSynthetic peptide (39 amino acids) with a fatty-acid side chain
Receptors activatedGIP, GLP-1 and glucagon (a “triple agonist”)
Molecular weightAbout 4,731 g/mol
Molecular formulaC221H342N46O68
CAS number2381089-83-2
Half-lifeAbout 6 days (once-weekly schedule in trials)
StatusInvestigational; Phase 3 trials (the TRIUMPH program); not FDA-approved

What is retatrutide?

Retatrutide is one molecule designed to do the work of three hormones. The body makes GLP-1 and GIP in the gut after a meal, and glucagon in the pancreas. Each hormone acts on its own receptor, and each receptor influences appetite, blood sugar, fat metabolism or energy use in a different way.

Earlier drugs in this family targeted one of these receptors (semaglutide acts on GLP-1) or two of them (tirzepatide acts on GIP and GLP-1). Retatrutide adds the third, the glucagon receptor. Researchers are testing whether hitting all three at once produces larger metabolic effects than one or two alone.

Is retatrutide a peptide?

Yes. Retatrutide is a chain of 39 amino acids, built on a GIP-like backbone. A few of its building blocks are non-natural amino acids that make it resistant to the enzyme (DPP-4) that normally breaks down GLP-1 and GIP within minutes. It also carries a fatty-acid side chain, which is covered in the structure section below.

Is retatrutide a GLP-1?

Partly. Retatrutide does activate the GLP-1 receptor, so it is often grouped with “GLP-1 drugs.” But it is not only a GLP-1 agonist: it also activates the GIP and glucagon receptors, which is exactly what sets it apart.

How does retatrutide work?

Retatrutide’s mechanism of action comes down to its three receptors. Each one contributes something different.

1. The GLP-1 receptor

GLP-1 receptor activation is the best-understood part of this drug class. It prompts the pancreas to release insulin when blood sugar is high (and not when it is low), lowers glucagon release after meals, slows how quickly the stomach empties, and acts on appetite centers in the brain to increase fullness.

2. The GIP receptor

GIP is the other major gut hormone released after eating. It also supports glucose-dependent insulin release, and it acts on fat tissue and the brain. In laboratory studies, retatrutide was more potent at the GIP receptor than the body’s own GIP, which makes GIP its strongest target of the three.

3. The glucagon receptor

This is the new ingredient. Glucagon is usually thought of as the hormone that raises blood sugar, but it also increases energy expenditure and pushes the liver to burn fat. Adding glucagon activity is meant to increase how much energy the body uses, not just reduce how much food comes in. Retatrutide is less potent than native glucagon at this receptor, and the GLP-1 and GIP activity helps offset glucagon’s blood-sugar-raising effect.

Why combine all three?

Put simply: GLP-1 and GIP mainly reduce intake and improve blood sugar control, while glucagon mainly increases energy use and liver fat burning. Combining them in one molecule lets researchers test both sides of the energy balance at once. Retatrutide is deliberately “unbalanced,” strongest at GIP and weaker than the native hormones at GLP-1 and glucagon, so the three effects are tuned relative to each other rather than simply maxed out.

Retatrutide’s structure

Three design features explain how retatrutide behaves:

  • A GIP-based backbone tuned so the same chain can also activate the GLP-1 and glucagon receptors.
  • Non-natural amino acids (such as aminoisobutyric acid, “Aib”) at key positions that block breakdown by DPP-4.
  • A C20 fatty diacid side chain attached through a linker. This lets the peptide bind to albumin, the most common protein in blood, which protects it from being cleared by the kidneys and stretches its activity out over days.

The same fatty-acid approach is used in semaglutide and tirzepatide, and it is what makes once-weekly schedules possible for all three.

Retatrutide half-life

In early human studies retatrutide’s half-life was about 6 days. That is slightly longer than tirzepatide (about 5 days) and similar to semaglutide (about 7 days), and it is why every retatrutide trial so far has used once-weekly administration.

What the clinical trials have reported

Retatrutide has moved through the standard drug development stages: Phase 1 (safety and pharmacology), Phase 2 (early efficacy) and now Phase 3 (large confirmatory trials). The headline findings published so far:

  • Phase 2, obesity (Jastreboff et al., New England Journal of Medicine, 2023): in 338 adults with obesity or overweight, mean body-weight reduction at 48 weeks reached 24.2% in the highest-dose group, versus 2.1% with placebo. Weight was still falling when the trial ended.
  • Phase 2, type 2 diabetes (Rosenstock et al., The Lancet, 2023): retatrutide produced dose-dependent reductions in HbA1c (average blood sugar) and body weight compared with placebo and with dulaglutide.
  • Liver fat (Sanyal et al., Nature Medicine, 2024): in a sub-study of the obesity trial, participants with fatty liver disease saw large reductions in liver fat, which fits the glucagon receptor’s role in liver fat burning.
  • Phase 3 (the TRIUMPH program): several large trials covering obesity, type 2 diabetes, knee osteoarthritis, sleep apnea and cardiovascular disease. The first Phase 3 results began reading out in late 2025, with more expected through 2026.

These are results from controlled trials under medical supervision. They describe what was measured in those studies, not what any individual should expect.

Side effects reported in trials

People often search “is retatrutide safe?” The honest answer is that its safety profile is still being established in Phase 3. What the published trials have reported so far:

  • Gastrointestinal effects were the most common: nausea, diarrhea, vomiting and constipation. They were mostly mild to moderate, dose-related, and most frequent while the dose was being increased. The trials found that starting at a lower dose reduced them.
  • Heart rate increases that were dose-dependent, peaked partway through the trial and then eased. This is also seen with other drugs in the class and is being monitored in Phase 3.
  • The longer-term and rarer risks will only be clear once the full Phase 3 data are published and reviewed by regulators.

Is retatrutide FDA approved?

No. Retatrutide is investigational and has not been approved by the FDA or any other major regulator. The usual sequence is: complete the Phase 3 program, submit an application, then undergo FDA review, which typically takes about 10 to 12 months. Until an approval is announced, no retatrutide product is an approved medicine.

Retatrutide vs tirzepatide vs semaglutide

SemaglutideTirzepatideRetatrutide
ReceptorsGLP-1GIP + GLP-1GIP + GLP-1 + glucagon
NicknameSingle agonistDual agonistTriple agonist
Half-lifeAbout 7 daysAbout 5 daysAbout 6 days
DeveloperNovo NordiskEli LillyEli Lilly
FDA statusApprovedApprovedInvestigational

For a deeper side-by-side, see Retatrutide vs Tirzepatide: Key Differences Explained and What Is Tirzepatide? For laboratory solution math, see the retatrutide reconstitution calculator.

Frequently asked questions

What is retatrutide?

Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied in clinical trials for obesity, type 2 diabetes and related conditions and is not FDA-approved.

Is retatrutide a peptide?

Yes. It is a synthetic peptide of 39 amino acids with a fatty-acid side chain that lets it bind albumin in the blood and stay active for days.

Is retatrutide a GLP-1?

It activates the GLP-1 receptor, but it is not only a GLP-1 drug. It also activates the GIP and glucagon receptors, which is why it is called a triple agonist.

What is the half-life of retatrutide?

About 6 days in early clinical studies, which is why trials give it once a week.

Is retatrutide FDA approved?

No. It is still investigational. Any approval would follow completion of the Phase 3 program and an FDA review.

Sources

  • Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metabolism, 2022.
  • Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b study. The Lancet, 2022.
  • Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine, 2023.
  • Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial. The Lancet, 2023.
  • Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. Nature Medicine, 2024.
  • ClinicalTrials.gov listings for the TRIUMPH Phase 3 program.

This article is for educational purposes only and is not medical advice. Retatrutide is an investigational compound that is not approved for human use.